Follow-up Safety Trial in Children With Chronic Heart Failure Therapy Receiving Orodispersible Minitablets of Enalapril
A phase 2/3 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 100 participants.
Also called NCT02654678
- Study
- In this atlas
Overview
- Design
- Interventional study; allocation not applicable; no masking; primary purpose treatment
- Phase
- Phase 2/3
- Enrolled
- 100 participants
- Sponsor
- Ethicare GmbH
- Registry
-
NCT02654678 -
2015-002397-21
-
- Start date
- (registry gives no type)
- Primary completion
- (anticipated)
- Completion
- (anticipated)
- Countries
- Austria, Hungary, Netherlands, Serbia, United Kingdom
- Registry status
- Unknown status
Technical summary
Registry record NCT02654678. Allocation not applicable; no masking; primary purpose treatment. Start 2016-03 (registry gives no type); primary completion 2018-04 (anticipated). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Follow-up Safety Trial in Children With Chronic Heart Failure Therapy Receiving Orodispersible Minitablets of Enalapril
- Acronym
- LENA-WP10
- Condition
- Heart Failure
- Condition
- Dilated Cardiomyopathy
- Condition
- Congenital Heart Disease
- Intervention (Drug)
- Enalapril Orodispersible Minitablet
- Lead sponsor
- Ethicare GmbH
Record details
- Record id
cardio:ct-nct02654678- Content hash
830c9abe4f89725ff59205f9bd67caccbebee151e40c35d6f3f5dfc7514bdd4a